Thrombosis Research
Volume 122, Issue 3 , Pages 336-345 , 2008

Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests

  • Boris Shenkman

      Affiliations

    • Amalia Biron Research Institute of Thrombosis and Hemostasis, Israel
    • B. Shenkman and S. Matetzky contributed equally to this study.
    • ,
  • Shlomi Matetzky

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel
    • B. Shenkman and S. Matetzky contributed equally to this study.
    • ,
  • Paul Fefer

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel
    • ,
  • Hanoch Hod

      Affiliations

    • Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel
    • ,
  • Yulia Einav

      Affiliations

    • Quantitative Biology Unit, Faculty of Sciences, Holon Institute of Technology, Holon, Israel
    • ,
  • Aharon Lubetsky

      Affiliations

    • Amalia Biron Research Institute of Thrombosis and Hemostasis, Israel
    • ,
  • David Varon

      Affiliations

    • Coagulation Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    • ,
  • Naphtali Savion

      Affiliations

    • Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • Corresponding Author InformationCorresponding author. Goldschleger Eye Research Institute, Sheba Medical Center, Tel Hashomer 52621, Israel. Tel.: +972 3 5302954; fax: +972 3 5351577.

Received 19 June 2007 ,Revised 1 October 2007 ,Accepted 22 October 2007.

References 

  1. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarjan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  2. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, et al. CREDO investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  3. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542–549
  4. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–2913
  6. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980–1987
  7. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implication. Ann Intern Med. 2005;142:370–380
  8. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–3175
  9. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med. 2007;167:1593–1599
  10. Gurbel PA, Kevin PB. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91:1123–1125
  11. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246–251
  12. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005;51:957–965
  13. Harrison P, Segal H, Balsbery K, Furtado C, Silber L, Rothwell PM. Screening for aspirin responsiveness after transient ischaemic attack and stroke. Comparison of 2-point-of-care-platelet function tests with optical aggregometry. Stroke. 2005;36:1001–1005
  14. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430–436
  15. Barragan P, Bouvier JL, Roquebert PO, Nacaluso G, Commeau P, Cornet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003;59:295–302
  16. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz , Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85–92
  17. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252:233–238
  18. Seyfarth HJ, Koksch M, Roethig C, Rother T, Neugebauer A, Klein N, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002;143:118–123
  19. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004;93:679–684
  20. Eikelboom JW, Hankey CJ. Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs. 2004;4:57–67
  21. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166–171
  22. Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E, et al. A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets. 2005;16:293–299
  23. Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res. 1997;85:283–294
  24. Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J. 1998;135:S187–S193
  25. Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res. 2000;99:353–3561
  26. Savion N, Shenkman B, Tamarin I, Dardik R, Frojmovic M, Varon D. Transient adhesion refractoriness of circulating platelets under shear stress: the role of partial activation and microaggregate formation by suboptimal ADP concentration. Br J Haematol. 2001;112:1055–1061
  27. Gurbel PA, Bilden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45:1392–1396
  28. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002;90:893–895
  29. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol. 2003;41:966–968
  30. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res. 2005;115:25–29
  31. Galvani M. High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?. J Thromb Haemost. 2006;4:536–538
  32. Cattaneo M, Gachet C, Cazenave JP, Packham MA. Adenosine diphosphate (ADP) does not induce thromboxane A2 generation in human platelets. Blood. 2002;99:3668–3669
  33. Abdelrahman N, Brill A, Touretsky N, Mosseri E, Mosseri M, Varon D. High rate of aspirin resistance among patients undergoing per-cutaneous intervention for unstable angina is associated with clinical outcome. Blood. 2004;104:515a;(Abstract, 46th Annual Meeting of ASH)
  34. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005;108:180–192
  35. Shankar H, Kahner B, Kunapuli SP. G-protein dependent platelet signaling-perspectives for therapy. Curr Drug Targets. 2006;7:1253–1263
  36. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 2004;25:476–483
  37. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2006;47:27–33
  38. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157–1164
  39. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res. 2005;115:89–94

PII: S0049-3848(07)00422-7

doi: 10.1016/j.thromres.2007.10.018

Thrombosis Research
Volume 122, Issue 3 , Pages 336-345 , 2008

Article Tools

* Image Usage & Resolution